MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.68
+0.43
+4.59%
After Hours: 9.68 0 0.00% 16:38 12/06 EST
OPEN
9.33
PREV CLOSE
9.26
HIGH
9.69
LOW
9.25
VOLUME
271.43K
TURNOVER
--
52 WEEK HIGH
32.32
52 WEEK LOW
7.43
MARKET CAP
473.52M
P/E (TTM)
-2.6850
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGNX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MGNX News

  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18
  • MacroGenics -6.1% premarket as Morgan Stanley turns bear
  • seekingalpha.11/21 18:20
  • UPDATE: Morgan Stanley On MacroGenics Notes 'Despite positive trends, we see F-allele data as unlikely to be on label. MGNX has a broad pipeline but we need to see more data before gaining confidence'
  • Benzinga.11/21 17:09
  • UPDATE: Morgan Stanley Downgrades MacroGenics To Underweight, Lowers Tgt From $17 To $6 Notes 'Margetuximab is expected to be approved but with limited market opportunity in 4L+ patients'
  • Benzinga.11/21 17:08

More

Industry

Biotechnology & Medical Research
+1.28%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About MGNX

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
More

Webull offers MacroGenics Inc (MGNX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.